Inhibitors of bruton's tyrosine kinase
View Patent ↗Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
1. A compound having the structure of Formula (D5):
wherein:
La is CH 2 , O, NH or S;
Ar is a substituted or unsubstituted aryl;
Y is a 4-, 5-, 6-, or 7-membered cycloalkyl ring, or
Y is a 4-, 5-, 6-, or 7-membered monocyclic nitrogen-containing heterocycloalkyl ring;
Z is C(═O), OC(═O), NHC(═O), S(═O) x , or NHS(═O) x , where x is 1 or 2;
R 8 is H;
R 7 is H, unsubstituted C 1 -C 4 alkyl, C 1 -C 6 alkoxyalkyl, C 1 -C 8 alkylaminoalkyl, or C 1 -C 4 alkyl(phenyl); or
R 7 and R 8 taken together form a bond;
R 6 is H, unsubstituted C 1 -C 4 alkyl, C 1 -C 6 alkoxyalkyl, C 1 -C 8 alkylaminoalkyl, or C 1 -C 4 alkyl(phenyl); or a pharmaceutically acceptable salt thereof.
2. The compound of claim 1 wherein La is O.
3. The compound of claim 2 wherein Z is C(═O), NHC(═O), or S(═O) 2 .
4. The compound of claim 3 wherein each of R 7 and R 8 is H or R 7 and R 8 taken together form a bond.
5. The compound of claim 3 wherein R 6 and R 8 are each H.
6. The compound of claim 1 wherein Y is a 5-membered monocyclic nitrogen-containing heterocycloalkyl ring.
7. The compound of claim 1 wherein Y is a 6-membered monocyclic nitrogen-containing heterocycloalkyl ring.
8. The compound of claim 1 wherein Ar is an unsubstituted phenyl.
9. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable excipient.
10. The compound of claim 1 , having the structure of:
11. A pharmaceutical composition comprising a compound of claim 10 and a pharmaceutically acceptable excipient.